TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines
Nicola Maurea(Cancer Institute (WIA)), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annamaria Bonelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gabriele Conforti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Simona Buccolo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vincenzo Quagliariello(Cancer Institute (WIA)), Antonietta Caronna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Cerrone
Cited by 5
Related Papers
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Basic principles of biobanking: from biological samples to precision medicine for patients
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2021|223